Ethanol (EtOH) self-administration is particularly sensitive to the modulation of CB1 signaling in the nucleus accumbens (NAc) shell, and EtOH consumption increases extracellular levels of the endogenous cannabinoid CB1 receptor agonist 2-arachidonoyl glycerol (2-AG) in this brain region. Stimulation of CB1 receptor with agonists increases EtOH consumption, suggesting that EtOH-induced increases in 2-AG might sustain motivation for EtOH intake. In order to further explore this hypothesis, we analyzed the alterations in operant EtOH self-administration induced by intra-NAc shell infusions of 2-AG itself, the CB1 inverse agonist SR141716A, the 2-AG clearance inhibitor URB602, anandamide, and the cyclooxygenase-2 (COX-2) inhibitor nimesulide. ...
Rationale A major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is t...
A major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is that these ...
RationaleA major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is th...
2-Arachidonoylglycerol (2-AG) is the most potent endogenous ligand of brain cannabinoid CB1 receptor...
2-Arachidonoylglycerol (2-AG) is the most potent endogenous ligand of brain cannabinoid CB1 receptor...
2-Arachidonoylglycerol (2-AG) is the most potent endogenous ligand of brain cannabinoid CB1 receptor...
The endocannabinoid system mediates in the pharmacological actions of ethanol and genetic studies li...
The endocannabinoid system mediates in the pharmacological actions of ethanol and genetic studies li...
A major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is that these ...
Rationale A major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is t...
Rationale A major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is t...
Augmentation of endogenous cannabinoid (eCB) signaling represents an emerging approach to the treatm...
Rationale A major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is t...
RationaleA major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is th...
A major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is that these ...
Rationale A major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is t...
A major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is that these ...
RationaleA major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is th...
2-Arachidonoylglycerol (2-AG) is the most potent endogenous ligand of brain cannabinoid CB1 receptor...
2-Arachidonoylglycerol (2-AG) is the most potent endogenous ligand of brain cannabinoid CB1 receptor...
2-Arachidonoylglycerol (2-AG) is the most potent endogenous ligand of brain cannabinoid CB1 receptor...
The endocannabinoid system mediates in the pharmacological actions of ethanol and genetic studies li...
The endocannabinoid system mediates in the pharmacological actions of ethanol and genetic studies li...
A major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is that these ...
Rationale A major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is t...
Rationale A major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is t...
Augmentation of endogenous cannabinoid (eCB) signaling represents an emerging approach to the treatm...
Rationale A major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is t...
RationaleA major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is th...
A major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is that these ...
Rationale A major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is t...
A major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is that these ...
RationaleA major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is th...